Compare S&P500 ETF (SPY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P500 ETF vs TG Therapeutics Inc — how do they compare? S&P500 ETF trades at $764.45, while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). Which is the better fit depends on your goals.
| SPY | TGTX | |
|---|---|---|
52-Week High | $777.82 | $59.06 |
52-Week Low | $631.99 | $26.94 |
Market Cap | — | $8.53B |
Sector | — | Health |
Enterprise Value | — | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPY trades at $766.00, down 0.55% on the day, with a neutral technical signal and bullish moving averages. Support levels are near $760, while resistance sits at $769. The ETF shows no available valuation ratios like P/E or P/B in the data. A dividend of $1.90 is scheduled for payment on July 31, 2026.
Outlook remains mixed amid market volatility from geopolitical tensions and oil price surges. Risks include Fed rate-hike concerns and high valuations, but AI-driven earnings growth offers potential upside. Investors should weigh resilience against near-term headwinds for long-term positioning.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
